Turan Burak, Erkol Ayhan, Gül Mehmet, Fındıkçıoğlu Uğur, Erden İsmail
Cardiology Department, Kocaeli Derince Training and Research Hospital, Kocaeli, Istanbul, Turkey.
Cardiology Department, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
Cardiorenal Med. 2015 Apr;5(2):116-24. doi: 10.1159/000371900. Epub 2015 Feb 28.
Contrast-induced nephropathy (CIN) has been traditionally associated with increased mortality and adverse cardiovascular events. We sought to determine whether CIN has a negative impact on the long-term outcome of patients with non-ST segment elevation myocardial infarction (NSTEMI).
A total of 312 consecutive patients (mean age 59 years, 76% male) who presented with NSTEMI and had undergone an early invasive procedure were retrospectively included. CIN was defined as either a 25% or 0.5-mg/dl increase in baseline serum creatinine (Cr) 72 h after the procedure. The primary endpoint of the study was mortality in the long-term follow-up (38 months, interquartile range 30-40). The secondary endpoint consisted of mortality and myocardial infarction (MI).
CIN developed in 30 (9.6%) patients. Independent predictors of CIN were the contrast volume-to-Cr clearance ratio, left ventricular ejection fraction and hemoglobin concentration. The primary (20 vs. 8.5%, p = 0.042) and secondary endpoints (33.3 vs. 17%, p = 0.029) were observed more frequently in patients with CIN during long-term follow-up. The unadjusted odds ratio (OR) of CIN was 2.55 [95% confidence intervals (CI) 1.04-6.24, p = 0.040] for mortality and 2.15 (CI 1.09-4.25, p = 0.028) for mortality/MI. However, after adjustment for confounding factors, CIN was not an independent predictor of either mortality (OR 1.62, CI 0.21-12.57, p = 0.646) or mortality/MI (OR 1.12, CI 0.31-4.0, p = 0.860).
The effect of CIN on the long-term outcome of patients with NSTEMI was substantially influenced by confounding factors. CIN was a marker, rather than a mediator, of increased cardiovascular risk, and the baseline renal function was more conclusive as a long-term prognosticator.
传统观点认为,对比剂肾病(CIN)与死亡率增加及不良心血管事件相关。我们旨在确定CIN是否会对非ST段抬高型心肌梗死(NSTEMI)患者的长期预后产生负面影响。
回顾性纳入312例连续出现NSTEMI且接受了早期侵入性治疗的患者(平均年龄59岁,76%为男性)。CIN定义为术后72小时基线血清肌酐(Cr)升高25%或升高0.5mg/dl。该研究的主要终点是长期随访(38个月,四分位间距30 - 40)时的死亡率。次要终点包括死亡率和心肌梗死(MI)。
30例(9.6%)患者发生了CIN。CIN的独立预测因素为对比剂用量与Cr清除率之比、左心室射血分数和血红蛋白浓度。在长期随访中,CIN患者更频繁地出现主要终点(20%对8.5%,p = 0.042)和次要终点(33.3%对17%,p = 0.029)。CIN对于死亡率的未调整优势比(OR)为2.55 [95%置信区间(CI)1.04 - 6.24,p = 0.040],对于死亡率/MI的未调整优势比为2.15(CI 1.09 - 4.25,p = 0.028)。然而,在对混杂因素进行调整后,CIN不是死亡率(OR 1.62,CI 0.21 - 12.57,p = 0.646)或死亡率/MI(OR 1.12,CI 0.31 - 4.0,p = 0.860)的独立预测因素。
CIN对NSTEMI患者长期预后的影响在很大程度上受到混杂因素的影响。CIN是心血管风险增加的一个标志物,而非介导因素,并且基线肾功能作为长期预后指标更具决定性。